PPAR-y2 and PTPRD gene polymorphisms influence type 2 diabetes patients' response to pioglitazone in China

查看全文 作　　者：Qi [1,2]PEI;Qiong [3]HUANG;Guo-ping [1,4]YANGI;Ying-chun [5]ZHAO;Ji-ye [1]YIN;Min [4]SONG;Yi [1]ZHENG;Zhao-hui [6]MO;Hong-hao [1]ZHOU;Zhao-qian [1]LIU

机构地区：[1]Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha 41007~,Chinat;[2]Department of Pharmacy, Third Xiangya Hospital, Central South University, Changsha 410013, China;[3]Institute of ClinicalPharmacology, Anhui Medical University, Hefei 230032, China;[4]Center of Clinical Pharmacology, Third Xiangya Hospital, Central SouthUniversity, Changsha 410013, China;[5]Osteooorosis Research Center. CreiEhton University, Omaha, NE 68131, USA;[6]Department ofEndocrinology, Third Xiangya Hospital, Central South University, Changsha 410013, China

出　　处：《Acta Pharmacologica Sinica》索引2013年第34卷第2期,共7页

关键词：2型糖尿病基因多态性中国汉族人群吡格列酮过氧化物酶体增殖物激活受体患者 MALDI-TOF质谱分析高密度脂蛋白胆固醇

相关文献

参考文献（36）
引证文献（9）
耦合文献（0）

参考文献(36)

引证文献(9)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

PPAR-y2 and PTPRD gene polymorphisms influence type 2 diabetes patients' response to pioglitazone in China

参考文献(36)

引证文献(9)

用户提示